Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

The Transradial Approach Continues to Be the Best for Primary PCI

The transradial approach has been associated to lower mortality and bleeding rates in patients receiving primary PCI for ST elevation MI. 

El acceso radial continúa siendo la mejor opción para la angioplastia primaria

This had been called into question by the recent SAFARI-STEMI, but after including its outcomes in a new meta-analysis, the scales tilted slightly in favor of the transradial approach vs. the transfemoral. 

The transradial approach is associated to lower all-cause mortality, major bleeding and vascular complications with no differences in terms of MI, stroke or procedure duration. The only point in favor of the transfemoral approach is fluoroscopy time. 

The European guidelines have given the transradial approach a class IA recommendation, over the transfemoral, for experienced operators. The American guidelines have not made this recommendation yet (seeing as their operators are more cautious than the European). However, the evidence is conclusive and sooner or later the American guidelines will also change. 

Prior studies comparing both access sites do not have enough statistical power to show significant differences in hard points such as mortality (even though the meta-analysis outcomes were conclusive). 


Read also: Boston Scientific Discontinues Lotus Valve and Makes a New Bet.


The SAFARI-STEMI was not able to show differences in all-cause mortality or major bleeding at 30 days between access sites. 

This called for a meta-analysis, which included 16 randomized prior studies plus more recent SAFARI-STEMI to add up over 12000 patients.

Half the population received a glycoprotein IIb IIIa inhibitor during procedure.


Read also: Transcatheter Bariatric Surgery?


There were no significant differences in MI (RR 0.96; CI 95% 0.75-1.24), stroke (RR 1.37; CI 95% 0.82-2.29) or procedure duration. The only difference was shorter fluoroscopy time with the transfemoral approach. 

The difference was led by bleeding. For every 1000 transradial procedures operators will prevent 16 major bleeding events.

They also managed to prove that when the risk of bleeding is low, the difference in mortality rate disappears. This data tells the benefit in mortality of the transradial approach comes hand in hand with the lower bleeding rate. 


Read also: SOLACI Webinar – Innovation: Short Dual Therapy in Patients with High Bleeding Risk.


The adoption percentage among operators is still quite heterogeneous. While the US is still around 50%, Europe is already at 90% in the context of PCI. 

The idea that a more difficult approach will waste precious time in a procedure where reperfusion velocity determines prognosis still holds operators back. This idea stems from the first observational studies, in times when operators were still inexperienced.  

Original Title: Meta-analysis of transradial vs transfemoral access for percutaneous coronary intervention in patients with ST elevation myocardial infarction.

Reference: Jhand A et al. Am J Cardiol. 2020; Epub ahead of print. doi: 10.1016/j.amjcard.2020.11.016.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...